Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co., Ltd.
Qurient Co., Ltd.
Alnylam Pharmaceuticals
Takeda
Coherus Oncology, Inc.
Bayer
Intensity Therapeutics, Inc.
Celldex Therapeutics
Xencor, Inc.
MultiVir, Inc.